A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury.

ABSTRACT:

Objective

To assess the efficacy and tolerability of pregabalin for the treatment of central neuropathic pain after spinal cord injury (SCI).

Methods

Patients with chronic, below-level, neuropathic pain due to SCI were randomized to receive 150 to 600 mg/d pregabalin (n = 108) or matching placebo (n = 112) for 17 weeks. Pain was classified in relation to the neurologic level of injury, defined as the most caudal spinal cord segment with normal sensory and motor function, as above, at, or below level. The primary outcome measure was duration-adjusted average change in pain. Key secondary outcome measures included the change in mean pain score from baseline to end point, the percentage of patients with ≥30% reduction in mean pain score at end point, patient global impression o

SUBMITTER: Cardenas DD 

PROVIDER: S-EPMC3589291 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature